1. The Next Generation of Basal Insulins

3. Insulin Distribution in Normal Physiology

4. Distribution of Exogenous Insulin

5. Plasma Insulin Levels Before and After Glucose in Portal Vein, Hepatic Vein, and Hepatic Artery

6. Insulin Resistance, Overinsulinization, and T2DM

7. Relative Effects of Insulin Analogues

8. Weight Gain With Insulin Glargine and Insulin Detemir in T2DM

9. Insulin Degludec and Insulin Glargine: Half-life

10. Peglispro Single-dose Pharmacodynamics in Healthy Patients

11. Insulin Degludec

12. Insulin Degludec Pharmacodynamics in Patients With T1DM

13. Insulin Degludec: Duration of Action (0
Insulin Degludec: Duration of Action (0.6 U/kg dose) Smoothed BG-profiles of a 42h Clamp Study

14. Effect of Insulin Degludec on Glycemic Control

15. Insulin Degludec vs Insulin Glargine: Hypoglycemia Outcomes

16. Degludec Flexible or Fixed vs Glargine: FPG and Hypoglycemia in T2DM

17. BEGIN Once Long: Degludec vs Glargine Body Weight Outcomes in T2DM at 52 Weeks

18. U300 Formulation of Insulin Glargine

19. Glargine U300 vs U100 Pharmacodynamics

20. EDITION Program: Glargine U300 vs U100

21. EDITION 3: T2DM Study Design

22. EDITION 4: T1DM Study Design

23. EDITION 3: Mean Change in HbA1c With U300 vs U100 in T2DM

24. EDITION 4: Mean Change in HbA1c With U300 vs U100 in T1DM

25. EDITION 3: Nocturnal Hypoglycemia With U300 vs U100 in T2DM

26. EDITION 4: Nocturnal Hypoglycemia With U300 vs U100 in T1DM

27. EDITION 3: Weight Change With U300 vs U100 in T2DM

28. EDITION 4: Weight Change With U300 vs U100 in T1DM

29. EDITION: Glargine U300 vs U100 Adverse Event Profiles

30. PEGylated Lispro (Peglispro)

31. PEGylated Lispro (Peglispro): Hydrodynamic Characteristics

32. The Endothelial Sieve and Peglispro

33. Hepatic and Peripheral Action During Peglispro or Glargine IV Infusion

34. The Phase 3 IMAGINE Clinical Trial Program: Glargine and NPH Studies

35. IMAGINE-3 and -5: HbA1c

36. IMAGINE-3 and -5: Hypoglycemia

37. IMAGINE-3 and -5: Body Weight

38. IMAGINE-3 and -5: Alanine Aminotransferase

39. IMAGINE-3 and -5: Triglycerides

40. IMAGINE-3 and -5: Liver Fat Content

41. Abbreviations

42. Abbreviations (cont)